Risk factors for HCC in contemporary cohorts of patients with cirrhosis
Hepatology · 2023
DOI: 10.1002/hep.32434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology, 2023. Verfasst von Fasiha Kanwal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sections of Gastroenterology and Hepatology , Baylor College of Medicine , Houston , Texas , USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms, Liver Diseases, Alcoholic. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Background and Aims: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk. Approach and Results: We used data from two contemporary, prospective multiethnic cohorts of patients with cirrhosis: the Texas Hepatocellular Carcinoma Consortium Cohort and the Houston Veterans Administration Cirrhosis Surveillance Cohort. Patients with cirrhosis were enrolled from seven US centers and followed until HCC diagnosis, transplant, death, or June 30, 2021. We calculated the annual incidence rates for HCC and examined the effects of etiology, demographic, clinical, and lifestyle factors on the risk of HCC. We included 2733 patients with cirrhosis (mean age 60.1 years, 31.3% women). At enrollment, 19.0% had active HCV, 23.3% had cured HCV, 16.1% had alcoholic liver disease, and 30.1% had NAFLD. During 7406 person‐years of follow‐up, 135 patients developed HCC at an annual incidence rate of 1.82% (95% CI, 1.51–2.13). The annual HCC incidence rate was 1.71% in patients with cured HCV, 1.32% in patients with alcoholic liver disease, and 1.24% in patients with NAFLD cirrhosis. Compared to patients with NAFLD, the risk of progression to HCC was 2‐fold higher in patients with cured HCV (HR, 2.04; 95% CI, 1.24–3.35). Current smoking (HR, 1.63; 95% CI, 1.01–2.63) and overweight/obesity (HR, 1.79; 95% CI, 1.08–2.95) were also associated with HCC risk. Conclusions: HCC incidence among patients with cirrhosis was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with HCV cirrhosis and lower risk in those with NAFLD cirrhosis. Current smoking and overweight/obesity increased HCC risk across etiologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sections of Gastroenterology and Hepatology , Baylor College of Medicine , Houston , Texas , USA.
- Health Services Research, Department of Medicine , Baylor College of Medicine , Houston , Texas , USA.
- VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety , Michael E. DeBakey Veterans Affairs Medical Center , Houston , Texas , USA.
- Division of Digestive and Liver Diseases, Department of Medicine , UT Southwestern Medical Center , Dallas , Texas , USA.
- Texas Liver Institute , San Antonio , Texas , USA.
- Baylor University Medical Center , Dallas , Texas , USA.
ORCID-Profile: Fasiha Kanwal, Amit G Singal, Sumeet K Asrani, Aaron P Thrift
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Kanwal, F., Khaderi, S., Singal, A. G., Marrero, J. A., Loo, N., Asrani, S. K., Amos, C. I., Thrift, A. P., Gu, X., Luster, M., Al-Sarraj, A., Ning, J., & El-Serag, H. B. (2023). Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. https://doi.org/10.1002/hep.32434
Vancouver
Kanwal F, Khaderi S, Singal AG, Marrero JA, Loo N, Asrani SK, et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023. doi:10.1002/hep.32434
BibTeX
@article{Kanwal2023,
author = {Kanwal, Fasiha and Khaderi, Saira and Singal, Amit G and Marrero, Jorge A and Loo, Nicole and Asrani, Sumeet K and Amos, Christopher I and Thrift, Aaron P and Gu, Xiangjun and Luster, Michelle and Al-Sarraj, Abeer and Ning, Jing and El-Serag, Hashem B},
title = {Risk factors for HCC in contemporary cohorts of patients with cirrhosis},
journal = {Hepatology},
year = {2023},
doi = {10.1002/hep.32434}
}
EUVIMED